Research is key to future treatment
The BRC is a partnership between The Royal Marsden and The Institute of Cancer Research, London. It supports innovative translational research, taking leading-edge cancer research from the laboratory and rapidly translating it into a clinical setting.
What does the future hold for gynaecological cancers & sarcoma?
Register now for our patient & public engagement event on Tuesday 8 October 2019.
Latest news
News: Immunotherapy option for bowel cancer
A major new study reveals that bowel cancer patients who have become resistant to a widely used targeted treatment could benefit from immunotherapy.
Find out more
News: Response to gene-targeted drugs depends on cancer type
Cancers with the same genetic weaknesses respond differently to targeted drugs depending on the tumour type of the patient, new research reveals.
Find out more
News: New drug option for prostate cancer
A recent clinical trial has found a pioneering gene-targeted drug designed for breast cancer to be effective in 80 percent of men with BRCA-mutant prostate cancer
Find out more